Company: CMND
Filing Date: 2025-06-12
Form Type: POS AM
Source: 0001213900-25-053898
Chunk: 39

Company: Clearmind Medicine Inc.
Filing Date: 2025-06-12
Form: POS AM
Chunk 39
---
 and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file reports
and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange
Act.

We maintain a corporate website at https://www.clearmindmedicine.com/.
Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.

<div align='center'>26

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

The SEC allows us to incorporate by reference
information into this document. This means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for any information
superseded by information that is included directly in this prospectus or incorporated by reference subsequent to the date of this prospectus.

We incorporate by reference
the following documents or information that we have filed with the SEC:

| ● | The                                                                                           
 description our Common Shares, which is contained in our registration statement on Form       
 8-A filed with the SEC pursuant to the Exchange Act on November 9, 2022 (File No. 001-41557), 
 as amended by Exhibit                                                                         
 2.1 to the Company’s Annual Report on Form                                                    
 20-F for the fiscal year ended October 31, 2023, filed with the SEC on January 29,            
 2024.                                                                                         |

We will provide you without charge, upon your
written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents
which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to us at Clearmind
Medicine Inc., 101 – 1220 W. 6th Ave, Vancouver, BC V6H1A, Attention: Alan Rootenberg, Chief Financial Officer, telephone number: +1
973.536.1016.

<div align='center'>27</div>

1,126,480 Common Shares

<div align='center'>Clearmind Medicine Inc.

PRELIMINARY PROSPECTUS

,
2025

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 6. Indemnification of Directors, Officers and Employees.

Indemnification